Oritavancin

Product Overview

Oritavancin is an innovative, investigational hospital-based antibiotic with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria including staphylococcal strains with resistance to methicillin (MRSA) and vancomycin. The safety and efficacy has not been established by the FDA for any use; however, further clinical studies are expected to commence in 2009 to evaluate oritavancin.

We believe that oritavancin can become an important anti-infective for serious infections involving difficult-to-treat bacteria in difficult-to-treat hospitalized patients. Many of those critically ill patients are the same patients treated with our existing products. This synergy makes oritavancin a natural fit with our strategy and focus on critical care medicine.